Synonym
A 499; A499; A-499; Sulfapyridine; Plurazol; Pyriamid
IUPAC/Chemical Name
4-amino-N-(pyridin-2-yl)benzenesulfonamide
InChi Key
GECHUMIMRBOMGK-UHFFFAOYSA-N
InChi Code
InChI=1S/C11H11N3O2S/c12-9-4-6-10(7-5-9)17(15,16)14-11-3-1-2-8-13-11/h1-8H,12H2,(H,13,14)
SMILES Code
O=S(NC1=NC=CC=C1)(C2=CC=C(N)C=C2)=O
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO, not in water
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
249.29
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Sobolewska B, Deuter C, Zierhut M. Current medical treatment of ocular mucous membrane pemphigoid. Ocul Surf. 2013 Oct;11(4):259-66. doi: 10.1016/j.jtos.2013.02.003. Epub 2013 Jul 9. Review. PubMed PMID: 24112229.
2: Freeman HJ. Medical management of ulcerative colitis with a specific focus on 5-aminosalicylates. Clin Med Insights Gastroenterol. 2012 Oct 18;5:77-83. doi: 10.4137/CGast.S8673. eCollection 2012. Review. PubMed PMID: 24833937; PubMed Central PMCID: PMC3987765.
3: Intong LR, Murrell DF. Management of epidermolysis bullosa acquisita. Dermatol Clin. 2011 Oct;29(4):643-7. doi: 10.1016/j.det.2011.06.020. Epub 2011 Aug 15. Review. PubMed PMID: 21925011.
4: Cardones AR, Hall RP 3rd. Management of dermatitis herpetiformis. Dermatol Clin. 2011 Oct;29(4):631-5. doi: 10.1016/j.det.2011.06.015. Epub 2011 Aug 3. Review. PubMed PMID: 21925009.
5: Ingen-Housz-Oro S. [Linear IgA bullous dermatosis: a review]. Ann Dermatol Venereol. 2011 Mar;138(3):214-20. doi: 10.1016/j.annder.2011.01.010. Review. French. PubMed PMID: 21397151.
6: Kao J, Kwok K, Das KM. Inducing and maintaining remission in ulcerative colitis: role of high-dose, extended-release mesalamine. J Clin Gastroenterol. 2010 Sep;44(8):531-5. doi: 10.1097/MCG.0b013e3181db1a61. Review. PubMed PMID: 20495466.
7: Echols RM, Tillotson GS, Song JX, Tosiello RL. Clinical trial design for mild-to-moderate community-acquired pneumonia--an industry perspective. Clin Infect Dis. 2008 Dec 1;47 Suppl 3:S166-75. doi: 10.1086/591399. Review. PubMed PMID: 18986284.
8: Nikfar S, Rahimi R, Rezaie A, Abdollahi M. A meta-analysis of the efficacy of sulfasalazine in comparison with 5-aminosalicylates in the induction of improvement and maintenance of remission in patients with ulcerative colitis. Dig Dis Sci. 2009 Jun;54(6):1157-70. doi: 10.1007/s10620-008-0481-x. Epub 2008 Sep 4. Review. PubMed PMID: 18770034.
9: Tweats DJ, Blakey D, Heflich RH, Jacobs A, Jacobsen SD, Morita T, Nohmi T, O'Donovan MR, Sasaki YF, Sofuni T, Tice R; IWGT Working Group. Report of the IWGT working group on strategy/interpretation for regulatory in vivo tests II. Identification of in vivo-only positive compounds in the bone marrow micronucleus test. Mutat Res. 2007 Feb 3;627(1):92-105. Epub 2006 Nov 20. Review. PubMed PMID: 17113817; PubMed Central PMCID: PMC2790421.
10: Hanauer SB. Review article: high-dose aminosalicylates to induce and maintain remissions in ulcerative colitis. Aliment Pharmacol Ther. 2006 Oct;24 Suppl 3:37-40. Review. PubMed PMID: 16961743.
11: Desreumaux P, Ghosh S. Review article: mode of action and delivery of 5-aminosalicylic acid - new evidence. Aliment Pharmacol Ther. 2006 Sep;24 Suppl 1:2-9. Review. PubMed PMID: 16939423.
12: Cohen HD, Das KM. The metabolism of mesalamine and its possible use in colonic diverticulitis as an anti-inflammatory agent. J Clin Gastroenterol. 2006 Aug;40 Suppl 3:S150-4. Review. PubMed PMID: 16885699.
13: Jo Y, Matsumoto T, Iida M. [Drug therapy for ulcerative colitis: salazosulfapyridine and 5-ASA]. Nihon Rinsho. 2005 May;63(5):820-4. Review. Japanese. PubMed PMID: 15881176.
14: Rodríguez-Spong B, Price CP, Jayasankar A, Matzger AJ, Rodríguez-Hornedo N. General principles of pharmaceutical solid polymorphism: a supramolecular perspective. Adv Drug Deliv Rev. 2004 Feb 23;56(3):241-74. Review. PubMed PMID: 14962581.
15: Schroeder KW. Role of mesalazine in acute and long-term treatment of ulcerative colitis and its complications. Scand J Gastroenterol Suppl. 2002;(236):42-7. Review. PubMed PMID: 12408503.
16: Ardizzone S, Bianchi Porro G. Comparative tolerability of therapies for ulcerative colitis. Drug Saf. 2002;25(8):561-82. Review. PubMed PMID: 12113642.
17: Ragunath K, Williams JG. Review article: balsalazide therapy in ulcerative colitis. Aliment Pharmacol Ther. 2001 Oct;15(10):1549-54. Review. PubMed PMID: 11563993.
18: Golusin Z, Poljacki M, Preveden R, Stojanović S, Rajić N. [What do we know today about diaminodiphenylsulfone?]. Med Pregl. 2000 Jul-Aug;53(7-8):369-72. Review. Croatian. PubMed PMID: 11214480.
19: Paniker U, Levine N. Dapsone and sulfapyridine. Dermatol Clin. 2001 Jan;19(1):79-86, viii. Review. PubMed PMID: 11155588.
20: Stein RB, Hanauer SB. Comparative tolerability of treatments for inflammatory bowel disease. Drug Saf. 2000 Nov;23(5):429-48. Review. PubMed PMID: 11085348.
